154 related articles for article (PubMed ID: 21403007)
21. Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability.
Jelinek GA; Weiland TJ; Hadgkiss EJ; Marck CH; Pereira N; van der Meer DM
Neurol Res; 2015 Aug; 37(8):662-73. PubMed ID: 25905471
[TBL] [Abstract][Full Text] [Related]
22. Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis.
Sellebjerg F; Hedegaard CJ; Krakauer M; Hesse D; Lund H; Nielsen CH; Søndergaard HB; Sørensen PS
Mult Scler; 2012 Mar; 18(3):305-13. PubMed ID: 22020419
[TBL] [Abstract][Full Text] [Related]
23. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.
Malhotra S; Río J; Urcelay E; Nurtdinov R; Bustamante MF; Fernández O; Oliver B; Zettl U; Brassat D; Killestein J; Lechner-Scott J; Drulovic J; Chan A; Martinelli-Boneschi F; García-Merino A; Montalban X; Comabella M
Brain; 2015 Mar; 138(Pt 3):644-52. PubMed ID: 25586466
[TBL] [Abstract][Full Text] [Related]
24. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.
Sellebjerg F; Krakauer M; Hesse D; Ryder LP; Alsing I; Jensen PE; Koch-Henriksen N; Svejgaard A; Soelberg Sørensen P
Eur J Neurol; 2009 Dec; 16(12):1291-8. PubMed ID: 19558503
[TBL] [Abstract][Full Text] [Related]
25. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
26. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis.
Hong J; Zang YC; Hutton G; Rivera VM; Zhang JZ
J Neuroimmunol; 2004 Jul; 152(1-2):126-39. PubMed ID: 15223245
[TBL] [Abstract][Full Text] [Related]
27. MiR-126: a novel route for natalizumab action?
Meira M; Sievers C; Hoffmann F; Derfuss T; Kuhle J; Kappos L; Lindberg RL
Mult Scler; 2014 Sep; 20(10):1363-70. PubMed ID: 24598267
[TBL] [Abstract][Full Text] [Related]
28. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
30. Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers.
Oliveira EM; Simm RF; Dasic G; Morais MM; Perreira SL; Callegaro D
Arq Neuropsiquiatr; 2015 Sep; 73(9):736-40. PubMed ID: 26352489
[TBL] [Abstract][Full Text] [Related]
31. Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation.
Cox MB; Bowden NA; Scott RJ; Lechner-Scott J
Mult Scler; 2013 Sep; 19(10):1268-74. PubMed ID: 23401127
[TBL] [Abstract][Full Text] [Related]
32. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
[TBL] [Abstract][Full Text] [Related]
33. Change in disability profile and quality of life in multiple sclerosis patients: a five-year longitudinal study using the Multiple Sclerosis Impact Profile (MSIP).
Wynia K; van Wijlen AT; Middel B; Reijneveld SA; Meilof JF
Mult Scler; 2012 May; 18(5):654-61. PubMed ID: 21965423
[TBL] [Abstract][Full Text] [Related]
34. Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment.
García-Barragán N; Villar LM; Espiño M; Sádaba MC; González-Porqué P; Alvarez-Cermeño JC
Eur J Neurol; 2009 Mar; 16(3):380-5. PubMed ID: 19175382
[TBL] [Abstract][Full Text] [Related]
35. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
[TBL] [Abstract][Full Text] [Related]
36. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
38. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
[TBL] [Abstract][Full Text] [Related]
39. TRAIL gene expression analysis in multiple sclerosis patients.
Taheri M; Nemati S; Movafagh A; Saberi M; Mirfakhraie R; Eftekharian MM; Arsang-Jang S; Rezagholizadeh A; Sayad A
Hum Antibodies; 2016 May; 24(1-2):33-8. PubMed ID: 27472871
[TBL] [Abstract][Full Text] [Related]
40. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis.
Satoh J; Nakanishi M; Koike F; Miyake S; Yamamoto T; Kawai M; Kikuchi S; Nomura K; Yokoyama K; Ota K; Kanda T; Fukazawa T; Yamamura T
Neurobiol Dis; 2005 Apr; 18(3):537-50. PubMed ID: 15755681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
